1. Michielsen P, Ho El. Viral hepatitis B and hepatocellular carcinoma. Acta gastro-enterologica Belgica 2011; 74(1): 4-8.
2. Wilkins T, Zimmerman D, Schade RR. Hepatitis B: Diagnosis and Treatment. American Academy of Family Physicians 2010; 81(8): 965-972.
3. World Health Organization (WHO). Hepatitis B. Geneva, Switzerland: World Health Organization. Updated July 2015. Available from: www.who.int/mediacentre/factsheets/fs204/en
4. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. International Journal of Epidemiology 2005; 34: 1329-1339.
5. Oakes K. Hepatitis B: prevalence and pathophysiology. Nurse Times 2014; 110(7): 12-16.
6. Wasley A, Kruszon-Moran D, Kuhnert W. The Prevalence of Hepatitis B Virus Infection in the United States in the Era of Vaccination. Journal of Infectious Diseases 2010; 202(2): 192-201.
7. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B Virus Infection in Iran: A Systematic Review. Hepatitis Monthly 2008; 8(4): 281-294.
8. Alavian SM. Hepatitis B virus infection in Iran; Changing the epidemiology. Iranian Journal of Clinical Infectious Diseases 2010; 5(1): 51-61.
9. Aspinall EJ, Hawkins G , Fraser A, Hutchinson SJ, Goldberg D. Hepatitis B prevention, diagnosis, treatment and care: a review. Occupational Medicine 2011; 61(8): 531–540.
10. Tazhibi M, Hajivandi A, Tafti AD, Fallahzadeh H. The efficacy of hepatitis B vaccine in Iranian population: A systematic review and meta-analysis. Journal of Education and Health Promotion 2014; 3: 53.
11. Aspinall EJ, Hawkins G, Fraser A, Hutchinson SJ, Goldberg D. Hepatitis B prevention, diagnosis, treatment and care: a review. Occupational Medicine 2011;61:531–540.
12. Lu CY, Chang MH. Hepatitis B immunization: Is a booster necessary?. Hepatitis B Annual 2005; 2: 56-73.
13. McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, et al. Antibody Levels and Protection after Hepatitis B Vaccine: Results of a 22-Year Follow-Up Study and Response to a Booster Dose. Journal of Infectious Diseases 2009; 200 (9): 1390-1396.
14. Hassan S, Ziba F. Antibody titer in Iranian children 6 years after hepatitis B vaccine administration. Vaccine 2007; 25(17):3511-4.
15. Kelishadi R, Heshmat R, Motlagh ME, Majdzadeh R, Keramatian K, Qorbani M, et al. Methodology and early findings of the Third Survey of CASPIAN Study: A national school-based surveillance of students’ high risk behaviors. International Journal of Preventive Medicine. 2012;3:394-401.
16. Norouzirad R, Shakurnia AH, Assarehzadegan MA, Serajian A, Khabazkhoob M, et al. Serum Levels of Anti-Hepatitis B Surface Antibody Among Vaccinated Population Aged 1 to 18 Years in Ahvaz City Southwest of Iran. Hepatitis Monthly 2014; 14(1): e13625.
17. Jafarzadeh A, Montazerifar SJ. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth. Journal of Ayub Medical College Abbottabad 2006; 18(4): 4-9.
18. Tosun S, Deveci S, Kaplan Y, Kasirga E. Should a booster dose be administered in children after mass immunization for hepatitis B? Hepatitis Monthly 2011; 11(6):440–444.
19. Liao SS, Li RC, Li H, Yang JY, Zeng XJ, Gong J, et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 1999; 17(20-21):2661-6.
20. Aghakhani A, Banifazl M, Izadi N, McFarland W, Sofian M, Khadem-Sadegh A, et al. Persistence of antibody to hepatitis B surface antigen among vaccinated children in a low hepatitis B virus endemic area. World Journal of Pediatrics 2011; 7(4): 358-60.
)